AL 721

Drug Profile

AL 721

Alternative Names: Altrigen

Latest Information Update: 02 Feb 2001

Price : $50

At a glance

  • Originator Ethigen Corporation
  • Developer Ethigen Corporation; Penn Pharmaceutical Services; Polagus
  • Class Antivirals
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cervical cancer; Cystic fibrosis; HIV infections

Most Recent Events

  • 02 Feb 2001 Profile reviewed but no significant changes made
  • 20 Nov 2000 Discontinued-II for HIV infections treatment in United Kingdom (PO)
  • 03 Jun 1997 No-Development-Reported for Cervical cancer (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top